Increased sympathetic renal innervation in hemodialysis patients is the anatomical substrate of sympathetic hyperactivity in end-stage renal disease

Journal of the American Heart Association

Volumn 4, Issue 12, 2015, Pages

  Mauriello, Alessandro ^a   Rovella, Valentina ^a   Anemona, Lucia ^a   Servadei, Francesca ^a   Giannini, Elena ^a   Bove, Pierluigi ^a   Anselmo, Alessandro ^b   Melino, Gerry ^a   Di Daniele, Nicola ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

Author keywords

End stage renal disease; Hemodialysis; Histology; Sympathetic renal innervation

Indexed keywords

ADULT; ADVENTITIA; AGED; ARTICLE; AUTOPSY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; END STAGE RENAL DISEASE; FEMALE; HEMODIALYSIS PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERTENSION; KIDNEY ARTERY; KIDNEY INNERVATION; MALE; NEUROLOGIC DISEASE; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; SYMPATHETIC HYPERACTIVITY; SYMPATHETIC INNERVATION; ADRENERGIC NERVE; CASE CONTROL STUDY; COMPLICATION; HEMODIALYSIS; INNERVATION; KIDNEY; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; SYMPATHECTOMY; VASCULARIZATION;

ADRENERGIC FIBERS; AGED; CASE-CONTROL STUDIES; FEMALE; HUMANS; HYPERTENSION; KIDNEY; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL DIALYSIS; SYMPATHECTOMY;

EID: 85006224574     PISSN: None     EISSN: 20479980     Source Type: Journal    
DOI: 10.1161/JAHA.115.002426     Document Type: Article

References (34)

1. Converse RL Jr, Jacobsen TN, Toto RD, Jost CM, Cosentino F, Fouad-Tarazi F, Victor RG. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med. 1992;327:1912-1918.
2. Augustyniak RA, Tuncel M, Zhang W, Toto RD, Victor RG. Sympathetic overactivity as a cause of hypertension in chronic renal failure. J Hypertens. 2002;20:3-9.
3. Masuo K, Lambert GW, Esler MD, Rakugi H, Ogihara T, Schlaich MP. The role of sympathetic nervous activity in renal injury and end-stage renal disease. Hypertens Res. 2010;33:521-528.
4. Schlaich MP. Sympathetic activation in chronic kidney disease: out of the shadow. Hypertension. 2011;57:683-685.
5. Ortiz A, Covic A, Fliser D, Fouque D, Goldsmith D, Kanbay M, Mallamaci F, Massy ZA, Rossignol P, Vanholder R, Wiecek A, Zoccali C, London GM. Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure. Lancet. 2014;383:1831-1843.
6. Agarwal R. Systolic hypertension in hemodialysis patients. Semin Dial. 2003;16:208-213.
7. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Ford CE, Shulman NB, Stamler J. Blood pressure and end-stage renal disease in men. N Engl J Med. 1996;334:13-18.
8. Agarwal R, Flynn J, Pogue V, Rahman M, Reisin E, Weir MR. Assessment and management of hypertension in patients on dialysis. J Am Soc Nephrol. 2014;25:1630-1646.
9. Grassi G, Seravalle G, Quarti-Trevano F. The 'neuroadrenergic hypothesis' in hypertension: current evidence. Exp Physiol. 2010;95:581-586.
10. DiBona GF. Sympathetic nervous system and hypertension. Hypertension. 2013;61:556-560.
11. Grassi G, Quarti-Trevano F, Seravalle G, Arenare F, Volpe M, Furiani S, Dell'Oro R, Mancia G. Early sympathetic activation in the initial clinical stages of chronic renal failure. Hypertension. 2011;57:846-851.
12. Rubinger D, Backenroth R, Sapoznikov D. Sympathetic nervous system function and dysfunction in chronic hemodialysis patients. Semin Dial. 2013;26:333-343.
13. Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension. 2011;57:911-917.
14. Esler MD, Krum H, Schlaich M, Schmieder RE, Bohm M, Sobotka PA. Renal sympathetic denervation for treatment of drug-resistant hypertension: oneyear results from the Symplicity HTN-2 randomized, controlled trial. Circulation. 2012;126:2976-2982.
15. Veelken R, Schmieder RE. Renal denervation-implications for chronic kidney disease. Nat Rev Nephrol. 2014;10:305-313.
16. Thorp AA, Larsen RN, Schlaich MP. Renal sympathetic nerve ablation for the management of resistant hypertension: an update. Curr Opin Nephrol Hypertens. 2013;22:607-614.
17. Schlaich MP, Schmieder RE, Bakris G, Blankestijn PJ, Bohm M, Campese VM, Francis DP, Grassi G, Hering D, Katholi R, Kjeldsen S, Krum H, Mahfoud F, Mancia G, Messerli FH, Narkiewicz K, Parati G, Rocha-Singh KJ, Ruilope LM, Rump LC, Sica DA, Sobotka PA, Tsioufis C, Vonend O, Weber MA, Williams B, Zeller T, Esler MD. International expert consensus statement: percutaneous transluminal renal denervation for the treatment of resistant hypertension. J Am Coll Cardiol. 2013;62:2031-2045.
18. Krum H, Schlaich MP, Sobotka PA, Bohm M, Mahfoud F, Rocha-Singh K, Katholi R, Esler MD. Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study. Lancet. 2014;383:622-629.
19. Azizi M, Sapoval M, Gosse P, Monge M, Bobrie G, Delsart P, Midulla M, Mounier-Vehier C, Courand PY, Lantelme P, Denolle T, Dourmap-Collas C, Trillaud H, Pereira H, Plouin PF, Chatellier G. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial. Lancet. 2015;385:1957-1965.
20. Hering D, Mahfoud F, Walton AS, Krum H, Lambert GW, Lambert EA, Sobotka PA, Bohm M, Cremers B, Esler MD, Schlaich MP. Renal denervation in moderate to severe CKD. J Am Soc Nephrol. 2012;23:1250-1257.
21. Kiuchi MG, Maia GL, de Queiroz Carreira MA, Kiuchi T, Chen S, Andrea BR, Graciano ML, Lugon JR. Effects of renal denervation with a standard irrigated cardiac ablation catheter on blood pressure and renal function in patients with chronic kidney disease and resistant hypertension. Eur Heart J. 2013;34:2114-2121.
22. Schlaich MP, Bart B, Hering D, Walton A, Marusic P, Mahfoud F, Bohm M, Lambert EA, Krum H, Sobotka PA, Schmieder RE, Ika-Sari C, Eikelis N, Straznicky N, Lambert GW, Esler MD. Feasibility of catheter-based renal nerve ablation and effects on sympathetic nerve activity and blood pressure in patients with end-stage renal disease. Int J Cardiol. 2013;168:2214-2220.
23. Di Daniele N, De Francesco M, Violo L, Spinelli A, Simonetti G. Renal sympathetic nerve ablation for the treatment of difficult-to-control or refractory hypertension in a haemodialysis patient. Nephrol Dial Transplant. 2012;27:1689-1690.
24. Di Daniele N, Rovella V, Violo L, De Francesco M, Sperandio M, Spinelli A, Tesauro M, Romeo F, Simonetti G. Reduction of left ventricular hypertrophy detected by cardiac magnetic resonance in a patient after renal denervation. J Cardiovasc Med (Hagerstown). 2015;16:721.
25. Atherton DS, Deep NL, Mendelsohn FO. Micro-anatomy of the renal sympathetic nervous system: a human postmortem histologic study. Clin Anat. 2012;25:628-633.
26. Sakakura K, Ladich E, Cheng Q, Otsuka F, Yahagi K, Fowler DR, Kolodgie FD, Virmani R, Joner M. Anatomic assessment of sympathetic peri-arterial renal nerves in man. J Am Coll Cardiol. 2014;64:635-643.
27. Burke AP, Kolodgie FD, Farb A, Weber D, Virmani R. Morphological predictors of arterial remodeling in coronary atherosclerosis. Circulation. 2002;105:297-303.
28. Sakakura K, Ladich E, Edelman ER, Markham P, Stanley JR, Keating J, Kolodgie FD, Virmani R, Joner M. Methodological standardization for the pre-clinical evaluation of renal sympathetic denervation. JACC Cardiovasc Interv. 2014;7:1184-1193.
29. Chen PS, Chen LS, Cao JM, Sharifi B, Karagueuzian HS, Fishbein MC. Sympathetic nerve sprouting, electrical remodeling and the mechanisms of sudden cardiac death. Cardiovasc Res. 2001;50:409-416.
30. Vracko R, Thorning D, Frederickson RG. Nerve fibers in human myocardial scars. Hum Pathol. 1991;22:138-146.
31. Vracko R, Thorning D, Frederickson RG. Fate of nerve fibers in necrotic, healing, and healed rat myocardium. Lab Invest. 1990;63:490-501.
32. Bengel FM, Ueberfuhr P, Schiepel N, Nekolla SG, Reichart B, Schwaiger M. Effect of sympathetic reinnervation on cardiac performance after heart transplantation. N Engl J Med. 2001;345:731-738.
33. Zoccali C, Mallamaci F, Parlongo S, Cutrupi S, Benedetto FA, Tripepi G, Bonanno G, Rapisarda F, Fatuzzo P, Seminara G, Cataliotti A, Stancanelli B, Malatino LS. Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation. 2002;105:1354-1359.
34. Fukuda K, Kanazawa H, Aizawa Y, Ardell JL, Shivkumar K. Cardiac innervation and sudden cardiac death. Circ Res. 2015;116:2005-2019.